The stock of Immunovant Inc (IMVT) has gone down by -6.00% for the week, with a -8.56% drop in the past month and a -29.78% drop in the past quarter. The volatility ratio for the week is 1.09%, and the volatility levels for the past 30 days are 3.45% for IMVT. The simple moving average for the past 20 days is -3.21% for IMVT’s stock, with a -40.63% simple moving average for the past 200 days.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
The 36-month beta value for IMVT is also noteworthy at 0.59. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for IMVT is 68.14M, and at present, short sellers hold a 31.40% of that float. The average trading volume of IMVT on May 29, 2025 was 1.73M shares.
IMVT) stock’s latest price update
Immunovant Inc (NASDAQ: IMVT) has experienced a decline in its stock price by -1.33 compared to its previous closing price of 14.29. However, the company has seen a fall of -6.00% in its stock price over the last five trading days. businesswire.com reported 2025-05-21 that SAN DIEGO–(BUSINESS WIRE)–Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant’s controlling stockholder – in connection with Immunovant’s January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day’s closing.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Jefferies repeating the rating for IMVT by listing it as a “Hold.” The predicted price for IMVT in the upcoming period, according to Jefferies is $20 based on the research report published on March 03, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to IMVT, setting the target price at $36 in the report published on October 10th of the previous year.
IMVT Trading at -9.23% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.09% of loss for the given period.
Volatility was left at 3.45%, however, over the last 30 days, the volatility rate increased by 1.09%, as shares sank -7.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -29.57% lower at present.
During the last 5 trading sessions, IMVT fell by -6.00%, which changed the moving average for the period of 200-days by -49.86% in comparison to the 20-day moving average, which settled at $14.57. In addition, Immunovant Inc saw -43.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMVT starting from GEORGE V MIGAUSKY, who proposed sale 21,812 shares at the price of $14.58 back on May 21 ’25. After this action, GEORGE V MIGAUSKY now owns shares of Immunovant Inc, valued at $318,047 using the latest closing price.
GEORGE V MIGAUSKY, the Former Director of Immunovant Inc, proposed sale 28,188 shares at $14.58 during a trade that took place back on May 19 ’25, which means that GEORGE V MIGAUSKY is holding shares at $410,908 based on the most recent closing price.
Stock Fundamentals for IMVT
Current profitability levels for the company are sitting at:
- -270.14 for the present operating margin
- 0.9 for the gross margin
The net margin for Immunovant Inc stands at -255.14. The total capital return value is set at -1.15. Equity return is now at value -74.17, with -67.59 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -14127.65.
Currently, EBITDA for the company is -269.98 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 1346.92. The receivables turnover for the company is 0.67for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.04.
Conclusion
In summary, Immunovant Inc (IMVT) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
